Alumis Inc. (NASDAQ:ALMS) Given Average Rating of “Buy” by Analysts

Shares of Alumis Inc. (NASDAQ:ALMS) have earned a consensus rating of “Buy” from the eight analysts that are currently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $26.83.

Several brokerages have weighed in on ALMS. HC Wainwright cut their price target on Alumis from $30.00 to $26.00 and set a “buy” rating for the company in a report on Thursday, November 14th. Robert W. Baird started coverage on Alumis in a research note on Thursday, October 31st. They issued an “outperform” rating and a $25.00 target price for the company. Baird R W raised Alumis to a “strong-buy” rating in a research note on Thursday, October 31st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Alumis in a research note on Thursday, November 14th.

Institutional Trading of Alumis

Institutional investors have recently modified their holdings of the company. Samsara BioCapital LLC acquired a new position in Alumis during the third quarter valued at approximately $34,886,000. SR One Capital Management LP purchased a new position in shares of Alumis in the 2nd quarter valued at $26,067,000. Yu Fan acquired a new position in shares of Alumis during the 2nd quarter valued at $10,502,000. Ally Bridge Group NY LLC purchased a new stake in Alumis during the 2nd quarter worth $8,229,000. Finally, Towerview LLC increased its holdings in Alumis by 22.6% in the 3rd quarter. Towerview LLC now owns 380,000 shares of the company’s stock valued at $4,058,000 after purchasing an additional 70,000 shares in the last quarter.

Alumis Stock Up 7.9 %

NASDAQ:ALMS opened at $8.62 on Friday. The firm has a 50 day moving average price of $10.60. Alumis has a 1-year low of $7.66 and a 1-year high of $13.53.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.